safety and tolerability sglt2 inhibitors in the treatment of cardiac amyloidosis
Published 2 weeks ago • 25 plays • Length 2:47Download video MP4
Download video MP3
Similar videos
-
15:11
safety and tolerability of sglt2 inhibitors in cardiac amyloidosis—a clinical feasibility study
-
3:35
sglt-2 inhibitors, explained: how they work, their benefits and risks
-
1:06:15
a tale of salt and sugar: sglt2 inhibitors in cardiovascular disease
-
50:30
protocols for safe use of sglt2i and glp1ra in the hospital setting
-
14:06
sglt2 inhibitors: the story so far | john wilding
-
8:15
sglt2 inhibitors and heart failure
-
28:56
christine limonte, md - update on sglt2i: real-world use and special population
-
10:55
what are sglt2 inhibitors and how do they affect kidney disease?
-
1:37
health inequalities in red cell disorders
-
7:14
sglt2 inhibitors and cardiovascular outcomes in type 2 diabetes: vertis cv trial
-
3:23
what are sglt2 inhibitors - chronic kidney disease | uhl nhs trust
-
3:40
using sglt2 inhibitors to achieve cardiovascular benefits
-
11:30
reviewing the role of sglt2 inhibitors in heart failure
-
12:43
basic mechanisms of sglt2 inhibitors in the kidney
-
0:30
sglt2 inhibitors for diabetics
-
6:23
sglt2 inhibitors
-
22:15
sglt-2 inhibitors for type 2 diabetes - amel arnaout, md
-
19:44
ep 7 – appropriate use and safety profile of sglt2 inhibitors
-
49:58
the use of sodium-glucose cotransporter-2 (sglt2) inhibitors in stemi - weekly research conference
-
7:46
sglt2 inhibition and the prevention of maces
-
59:01
initiating and managing sglt2 inhibitors in type 2 diabetes webinar